Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000048987
Ethics application status
Approved
Date submitted
12/12/2019
Date registered
22/01/2020
Date last updated
8/09/2024
Date data sharing statement initially provided
22/01/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 cycles of temozolomide after chemoradiotherapy, or continue monthly treatment until disease progression
Scientific title
A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma. Initial questions of interest are: QUESTION 1: whether to give metronomic temozolomide as soon as possible following surgery prior to chemoradiotherapy; and QUESTION 2: whether to give a plan for 6 cycles of standard schedule adjuvant temozolomide chemotherapy (5/28 day cycles) after chemoradiotherapy, or continue temozolomide until progression.
Secondary ID [1] 300075 0
COGNO 19/03
Secondary ID [2] 300076 0
CTC 0252
Universal Trial Number (UTN)
Trial acronym
MAGMA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glioblastoma 315598 0
Condition category
Condition code
Cancer 313891 313891 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
For each treatment question, patients will be randomised to a specific arm, unless they specifically choose not to participate in that randomisation, in which case treatment will be at patient/doctor discretion. Temozolomide is administered orally and daily at below described doses for patients allocated to Arm 1 (intervention) of each question. Compliance will be determined at each clinic visit by obtaining the patient history and estimating the level of compliance.

QUESTION 1 whether to give temozolomide as soon as possible following surgery prior to chemoradiotherapy or start at same time when radiotherapy begins. Intervention Arm 1 - After surgery, start temozolomide as soon as possible prior to chemoradiotherapy. Initial treatment will be at 75mg/m2 per day and will continue through radiotherapy.

QUESTION 2 whether to give 6 cycles of adjuvant temozolomide after chemoradiotherapy or continue adjuvant temozolomide until disease progression. Intervention Arm 1 - After chemoradiotherapy, take adjuvant temozolomide until disease progression. Treatment will commence approximately 4 weeks following chemoradiotherapy. Cycle 1 will be given at 150mg/m2 and subsequent cycles at 200mg/m2 for days 1-5 of a 28 day cycle.

Participation in both or either questions will determined by patient eligibility and at the patient/doctor discretion.
Intervention code [1] 316348 0
Treatment: Drugs
Comparator / control treatment
For each treatment question, patients will be randomised to a specific arm, unless they specifically choose not to participate in that randomisation, in which case treatment will be at patient/doctor discretion. Temozolomide is administered orally and daily at below described doses for patients allocated to Arm 2 (control) of each question. Compliance will be determined at each clinic visit by obtaining the patient history and estimating the level of compliance.

QUESTION 1 whether to give temozolomide as soon as possible following surgery prior to chemoradiotherapy or start at same time when radiotherapy begins. Control Arm 2 - After surgery, start temozolomide at the same time as radiotherapy. Daily treatment at 75mg/m2 and will continue through radiotherapy.

QUESTION 2 whether to give 6 cycles of adjuvant temozolomide after chemoradiotherapy or continue adjuvant temozolomide until disease progression. Control Arm 2 - After chemoradiotherapy, take adjuvant temozolomide for 6 cycles. Treatment will commence approximately 4 weeks following chemoradiotherapy. Cycle 1 will be given at 150mg/m2 and subsequent cycles at 200mg/m2 for days 1-5 of a 28 day cycle for a maximum of 6 cycles in total.
Control group
Active

Outcomes
Primary outcome [1] 322282 0
The primary objective for each investigational question is to assess the effectiveness of that treatment on overall survival versus usual care.
Timepoint [1] 322282 0
Overall survival is defined as the interval from the date of initial surgery to the date of death from any cause, or censoring at the date of last known follow-up alive, and will be calculated using the Kaplan-Meier method. For the initial two questions of interest this timepoint will be assessed until 18 months follow-up.
Secondary outcome [1] 377943 0
Determine progression-free survival
Timepoint [1] 377943 0
Progression-free survival is defined as the interval between the date of initial surgery and the date of tumour progression or death from any cause, with censoring at last follow up if alive and progression-free. For the initial two questions of interest this timepoint will be assessed until 18 months follow-up.
Secondary outcome [2] 377944 0
Determine time to first non-temozolomide treatment for recurrent disease (including systemic treatment, re-resection, re-irradiation)
Timepoint [2] 377944 0
The time to first treatment for recurrent disease is defined as the interval between the date of initial surgery and the date of first treatment (e.g. re-resection, re-irradiation, 2nd line chemotherapy or a clinical trial treatment) or death from any cause, with censoring at last follow up if alive with no treatment for recurrent disease. For the initial two questions of interest this timepoint will be assessed until 18 months follow-up.
Secondary outcome [3] 377945 0
Understand clinically significant toxicity due to treatment will be assessed by clinical examinations. For the initial two questions of interest minor treatment-related toxicities will not recorded as the tolerance of temozolomide is well understood. Treatment-related toxicities clinically assessed grade 3 or grade 4 will be recorded.
Timepoint [3] 377945 0
Treatment-related Grade 3 or 4 adverse events will be recorded. Minor toxicity is not recorded for the initial two study arms as the tolerance of temozolomide is well understood. For the initial two questions of interest this timepoint will be assessed at the start of chemoradiotherapy (CRT), 4 weeks after start of CRT, 4 weeks after completion of CRT then 12 weekly until 30 days after completion of all study treatments,
Secondary outcome [4] 377946 0
Understand health-related quality of life
Timepoint [4] 377946 0
Health-related quality of life will be reported by participants using the EORTC core quality of life questionnaire (QLQ C-30) and brain cancer specific module (BN-20), and the EuroQol EQ-5D-5L.. All components will be combined into a single questionnaire and for the initial two questions of interest this timepoint will be assessed at registration for the trial, at the start of chemoradiotherapy, 4 weeks after the completion of chemoradiotherapy, then every 12 weeks for a minimum 18 months.

Eligibility
Key inclusion criteria
1. Adults, aged 18 years and older, with newly diagnosed histologically confirmed grade IV malignant glioblastoma (any IDH mutation status) or glioma with molecular features of GBM (e.g. IDH-wildtype grade III high grade glioma, which have been confirmed to have the same prognosis as glioblastoma (grade IV) patients, and are now functionally treated as GBM39)
2. Adequate recovery from surgical resection
3. ECOG performance status of 0-2
4. Previous surgery for a low-grade glioma is allowed, if there was no radiation or chemotherapy administered at that time
5. Adequate bone marrow function (platelets greater than or equal to 100 x 109/L, ANC greater than or equal to 1.5 x 109/L)
6. Adequate liver function (ALT/AST less than 3 x ULN)
7. Adequate renal function (creatinine clearance greater than 30ml/min)
8. Willing and able to comply with all study requirements, including treatment, timing and nature of required assessments
9. Signed, written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Recurrence of glioblastoma
2. Comorbidities considered to provide a safety concern for use of TMZ, e.g. idiopathic
autoimmune thrombocytopenia or other haematological diease causing cytopaenias
3. Other contraindications to TMZ
4. Cranial irradiation within 2 years prior to registration
5. Other co-morbidities or conditions that may compromise assessment of key outcomes
6. History of another malignancy within 2 years prior to registration. Patients with adequately treated carcinoma-in-situ of the prostate, breast or cervix, melanoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-muscle invasive transitional cell carcinoma of the bladder or low grade prostate cancer not requiring treatment (ISUP 1; Gleason grade less than or equal to 6) may be included in this study.
7. Concurrent illness, including severe or chronic bacterial or viral infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety. Patients with adequately treated hepatitis B, hepatitis C or human immunodeficiency virus at low risk of acquired immunodeficiency syndrome-related outcomes may be included in this study.
8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse
9. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Consenting participants will be allocated to treatment in a partial factorial design with optional randomisation. For each treatment question, patients will be randomised to a specific arm, unless they specifically choose not to participate in that randomisation, in which case treatment will be at patient/doctor discretion.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
For the initial treatment questions, consenting participants will be randomly allocated to treatment in a partial factorial design with optional randomisation. For each treatment question, patients will be randomised to a specific arm, unless they specifically choose not to participate in that question, in which case treatment will be at patient and doctor discretion.
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The overall design is a multi-arm, multi-stage, multi-centre, phase III platform study, Interim analyses will facilitate any of the following: closing of treatment questions/arms, introduction of new treatment questions/arms, graduation of successful treatments into the revised standard-of-care, and periodic re-estimation of effect size for sample size adaptation. Advisory stopping boundaries for efficacy and futility will be made available to the Independent Data Safety Monitoring Committee.

Only those patients randomised to at least one treatment question will be included in the primary analysis. Data from patients not randomised to either question will be collected and may be used in exploratory analyses.

For the initial two questions of interest, with 3 years’ accrual and 18 months’ follow-up a sample size of at least 125 patients per arm (250 randomised for each question, 200 observed deaths) would give 80% power at 5% two-sided alpha to detect a 33% improvement in deaths (HR 0.667) or an increase in median survival from 12 to 18 months. The study plan is to recruit a total of at least 300 patients, but as additional questions are approved by the Trial Management Committee, and if additional budget is available, the sample size may expand after appropriate ethics approvals.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
30/06/2020
Actual
15/09/2020
Date of last participant enrolment
Anticipated
31/07/2023
Actual
18/07/2023
Date of last data collection
Anticipated
31/12/2024
Actual
Sample size
Target
300
Accrual to date
Final
338
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA,VIC
Recruitment hospital [1] 17984 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [2] 17985 0
Gold Coast University Hospital - Southport
Recruitment hospital [3] 17986 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [4] 17987 0
Royal Hobart Hospital - Hobart
Recruitment hospital [5] 19767 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [6] 19768 0
Concord Repatriation Hospital - Concord
Recruitment hospital [7] 19769 0
Liverpool Hospital - Liverpool
Recruitment hospital [8] 19770 0
St George Hospital - Kogarah
Recruitment hospital [9] 19771 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [10] 19772 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [11] 19773 0
The Townsville Hospital - Douglas
Recruitment hospital [12] 20784 0
Prince of Wales Hospital - Randwick
Recruitment hospital [13] 20785 0
Nepean Hospital - Kingswood
Recruitment hospital [14] 20786 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [15] 20787 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [16] 20788 0
Westmead Hospital - Westmead
Recruitment hospital [17] 20789 0
Coffs Harbour Base Hospital - Coffs Harbour
Recruitment hospital [18] 20790 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [19] 20791 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [20] 20792 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [21] 20793 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment hospital [22] 20794 0
The Chris O’Brien Lifehouse - Camperdown
Recruitment hospital [23] 20795 0
Gosford Hospital - Gosford
Recruitment hospital [24] 22447 0
Border Medical Oncology - Albury
Recruitment hospital [25] 22448 0
Riverina Cancer Care Centre - Wagga Wagga
Recruitment hospital [26] 22449 0
Icon Integrated Cancer Centre North Lakes - North Lakes
Recruitment hospital [27] 22450 0
Toowoomba Hospital - Toowoomba
Recruitment hospital [28] 22451 0
Wollongong Hospital - Wollongong
Recruitment postcode(s) [1] 31942 0
2298 - Waratah
Recruitment postcode(s) [2] 31943 0
4215 - Southport
Recruitment postcode(s) [3] 31944 0
6009 - Nedlands
Recruitment postcode(s) [4] 31945 0
7000 - Hobart
Recruitment postcode(s) [5] 34409 0
2065 - St Leonards
Recruitment postcode(s) [6] 34410 0
2139 - Concord
Recruitment postcode(s) [7] 34411 0
2170 - Liverpool
Recruitment postcode(s) [8] 34412 0
2217 - Kogarah
Recruitment postcode(s) [9] 34413 0
4029 - Herston
Recruitment postcode(s) [10] 34414 0
4102 - Woolloongabba
Recruitment postcode(s) [11] 34415 0
4814 - Douglas
Recruitment postcode(s) [12] 35599 0
2031 - Randwick
Recruitment postcode(s) [13] 35600 0
2747 - Kingswood
Recruitment postcode(s) [14] 35601 0
3065 - Fitzroy
Recruitment postcode(s) [15] 35602 0
3084 - Heidelberg
Recruitment postcode(s) [16] 35603 0
2145 - Westmead
Recruitment postcode(s) [17] 35604 0
2450 - Coffs Harbour
Recruitment postcode(s) [18] 35605 0
3000 - Melbourne
Recruitment postcode(s) [19] 35606 0
3168 - Clayton
Recruitment postcode(s) [20] 35607 0
5042 - Bedford Park
Recruitment postcode(s) [21] 35608 0
2010 - Darlinghurst
Recruitment postcode(s) [22] 35609 0
2050 - Camperdown
Recruitment postcode(s) [23] 35610 0
2250 - Gosford
Recruitment postcode(s) [24] 37675 0
2640 - Albury
Recruitment postcode(s) [25] 37676 0
2650 - Wagga Wagga
Recruitment postcode(s) [26] 37677 0
4509 - North Lakes
Recruitment postcode(s) [27] 37678 0
4350 - Toowoomba
Recruitment postcode(s) [28] 37679 0
2500 - Wollongong

Funding & Sponsors
Funding source category [1] 304523 0
Government body
Name [1] 304523 0
Medical Research Future Fund
Country [1] 304523 0
Australia
Primary sponsor type
University
Name
NHMRC Clinical Trials Centre (CTC), University of Sydney
Address
The University of Sydney (USYD), City Rd, Darlington New South Wales 2008
Country
Australia
Secondary sponsor category [1] 304795 0
None
Name [1] 304795 0
Address [1] 304795 0
Country [1] 304795 0
Other collaborator category [1] 281307 0
Other Collaborative groups
Name [1] 281307 0
The Cooperative Trials Group for Neuro-Oncology (COGNO)
Address [1] 281307 0
Lifehouse, Level 6, 119-143 Missenden Road, Camperdown NSW 2050
Country [1] 281307 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304954 0
Royal Prince Alfred Hospital Ethics committee
Ethics committee address [1] 304954 0
Ethics committee country [1] 304954 0
Australia
Date submitted for ethics approval [1] 304954 0
02/12/2019
Approval date [1] 304954 0
28/02/2020
Ethics approval number [1] 304954 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 98758 0
A/Prof Craig Gedye
Address 98758 0
NHMRC Clinical Trials Centre
The Lifehouse Building, Level 6,
119-143 Missenden Road
Camperdown, NSW, 2050
Country 98758 0
Australia
Phone 98758 0
+61 2 9562 5000
Fax 98758 0
Email 98758 0
magma.study@sydney.edu.au
Contact person for public queries
Name 98759 0
MAGMA Trial Operations Coordinator
Address 98759 0
NHMRC Clinical Trials Centre
The Lifehouse Building, Level 6,
119-143 Missenden Road
Camperdown, NSW, 2050
Country 98759 0
Australia
Phone 98759 0
+61 2 9562 5000
Fax 98759 0
Email 98759 0
magma.study@sydney.edu.au
Contact person for scientific queries
Name 98760 0
MAGMA Trial Operations Coordinator
Address 98760 0
NHMRC Clinical Trials Centre
The Lifehouse Building, Level 6,
119-143 Missenden Road
Camperdown, NSW, 2050
Country 98760 0
Australia
Phone 98760 0
+61 2 9562 5000
Fax 98760 0
Email 98760 0
magma.study@sydney.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseMulti-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma.2022https://dx.doi.org/10.1136/bmjopen-2021-058107
N.B. These documents automatically identified may not have been verified by the study sponsor.